(9-122) Evaluation of the Efficacy and Safety of Factor Eight Inhibitor Bypassing Activity (FEIBA) Doses in Patients with Apixaban or Rivaroxaban Associated Intracranial Hemorrhage
Wednesday, December 7, 2022
8:30 AM – 9:30 AM
Location: Bayside A, Level 1
Category: Research-in-Progress Topic: Critical Care
